UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1, 2023

LEIDOS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

001-33072 (Commission File Number)

(I.R.S. Employer Identification No.)

1750 Presidents Street, Reston, Virginia

(Address of principal executive office)

(571) 526-6000

(Registrants' telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value \$.0001 per share	LDOS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

20-3562868 20190

(Zip Code)

Item 2.02. Results of Operations and Financial Condition.

On August 1, 2023, Leidos Holdings, Inc. (the "Company") issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report.

The Company's management will discuss operations and financial results in an earnings conference call beginning at 8:00 a.m. eastern on August 1, 2023. A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Investor Relations section of the Company's web site (<u>http://investors.leidos.com</u>).

The information contained in Item 2.02 of this report and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(i) Exhibits

Exhibit 99.1Press Release dated August 1, 2023, issued by Leidos Holdings, Inc.Exhibit 104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL and contained in Exhibit 101.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEIDOS HOLDINGS, INC.

Date: August 1, 2023

By: /s/ Christopher R. Cage

 Christopher R. Cage

 Its:
 Executive Vice President and Chief Financial Officer

Leidos Holdings, Inc. Reports Second Quarter Fiscal Year 2023 Results

- Revenues of \$3.8 billion, up 7% year-over-year
- Net Income of \$210 million (5.5% margin); Adjusted EBITDA of \$420 million (10.9% margin)
- Diluted Earnings per Share of \$1.50, or \$1.80 on a non-GAAP basis
- Cash Flows from Operations of \$164 million; Free Cash Flow of \$124 million
- Net Bookings of \$2.9 billion (book-to-bill ratio of 0.8)

RESTON, Va., August 1, 2023 – Leidos Holdings, Inc. (NYSE: LDOS), a FORTUNE 500[®] science and technology leader, today reported financial results for the second quarter of fiscal year 2023.

Thomas Bell, Leidos Chief Executive Officer, commented, "It is my honor to lead Leidos into its second decade of top-line growth, which we plan to complement with a sharper focus on earnings and cash through disciplined financial management. This focus is underscored by the strong second quarter results announced today, characterized by record revenues and adjusted EBITDA. Propelling our future performance, we will remain dedicated to resolving with pace the most challenging problems faced by our customers, our nation, and its allies—an approach that distinctly sets Leidos apart."

Summary Operating Results

Three Months Ended							
Jun	e 30, 2023	July 1, 2022					
\$	3,838 \$	3,597					
\$	210 \$	172					
	5.5 %	4.8 %					
\$	1.50 \$	1.24					
\$	420 \$	366					
	10.9 %	10.2 %					
\$	1.80 \$	1.59					
	\$ \$ \$ \$	June 30, 2023 \$ 3,838 \$ \$ 210 \$ 5.5 % \$ 1.50 \$ \$ 420 \$ 10.9 %					

* Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another measure of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures.

Revenues for the quarter were \$3.84 billion, up 7% compared to the second quarter of 2022. Revenues grew year-over-year primarily due to increased demand across all customer segments, especially for digital modernization, hypersonics, and medical examinations solutions.

Net income was \$210 million and diluted EPS was \$1.50. Net income and diluted EPS were up 22% and 21% year-over-year, respectively. Adjusted EBITDA was \$420 million for the second quarter, up 15% year-over-year. Adjusted EBITDA margin of 10.9% increased from 10.2% in the second quarter of 2022. Non-GAAP net income was \$252 million for the second quarter, up 15% year-over-year, and non-GAAP diluted EPS for the quarter was \$1.80, up 13% year-over-year.

The primary drivers of increased earnings were improved business mix and program execution within each segment as well as reduced indirect spending across the company.

Cash Flow Summary

In the second quarter Leidos generated \$164 million of net cash provided by operating activities and used \$44 million in investing activities and \$164 million in financing activities. Net cash provided by operating activities benefited from strong collections and working capital management. Days Sales Outstanding (DSO) for the quarter was 59, a 3-day improvement from the first quarter of 2023.

Investing activities consisted primarily of \$40 million in property, equipment and software payments, which resulted in quarterly free cash flow of \$124 million. Financing activities were driven by the payment of the remaining \$320 million of principal on the 364-day term loan credit agreement from May 6, 2022, netted against borrowings of \$200 million of commercial paper notes. In addition, Leidos returned \$50 million to shareholders in the second quarter as part of its regular quarterly cash dividend program. As of June 30, 2023, Leidos had \$329 million in cash and cash equivalents and \$4.9 billion of debt.

On July 28, 2023, the Leidos Board of Directors declared a cash dividend of \$0.36 per share to be paid on September 29, 2023, to stockholders of record at the close of business on September 15, 2023.

Business Development

Net bookings totaled \$2.9 billion in the quarter, representing a book-to-bill ratio of 0.8. As a result, backlog at the end of the quarter was \$34.2 billion, of which \$8.3 billion was funded. Included in the quarterly bookings were several notable awards:

- Common Hypersonics Glide Body (CHGB) Follow-On. The U.S. Army Program Executive Office Missiles and Space (PEO MS) awarded Leidos a four-year, \$428 million prime contract to develop and test new CHGB prototypes. Under this follow-on, the Dynetics team expects to build up to 31 new CHGB prototypes to support Army and Navy requirements.
- Centers for Medicare and Medicaid Services (CMS) Office of Information Technology End-User Centric IT Support. The CMS OIT awarded Leidos a contract with a total estimated value of \$197 million over five years to provide seat-management services for CMS OIT employees and contractors and their personal computers, mobile devices and productivity services enabled through those devices. Under the contract, Leidos will continue to deliver engineering, innovation and accessibility compliance support to an onsite and remote workforce with a focus on fostering a positive end-user experience.
- Royal Saudi Air Force (RSAF) Contractor Engineering & Technical Services Follow-On (CETS V). The RSAF awarded Leidos a
 contract with a total estimated value of \$105 million over four years to maintain and enhance RSAF Command, Control,
 Communications, Computers and Intelligence (C4I) systems, including ground communications, radars, and IT systems, and support
 various aircraft platforms and systems support programs.
- Defense Enclave Services (DES) DoDNet Planning and Design (DPAD). The Defense Information Systems Agency (DISA) awarded Leidos a DES task order with a total estimated value of \$69 million over 55 months to migrate 14 Defense Agencies and Field Activities (DAFAs) to DoDNet. This award is the second task order under the DES effort to consolidate enterprise IT services and provide standardized, responsive and cost-effective solutions for more than 370,000 users spanning 22 Department of Defense (DoD) agencies and field activities with over 500 sites both in the U.S. and abroad. The work will focus on mission value and user experience, while improving cybersecurity, network availability and reliability.

In addition, Leidos expanded its partnership network in support of technology offerings. As part of a Trusted Generative AI campaign, Leidos strengthened its collaboration with industry leaders, harnessing shared expertise to drive innovation in AI. These partnerships allow Leidos to work with the most advanced models available—from OpenAI's GPT-4 through Microsoft to Google's Bard and Amazon's Bedrock. This collaboration enables secure environments that protect sensitive data while leveraging the power of Generative AI. In addition, Leidos and Aalyria have partnered to integrate Aalyria's Spacetime networking technology with Leidos' global-scale network management and protection solutions for critical government missions. By integrating Spacetime into new and existing solutions, the companies are developing multi-domain mission infrastructure capabilities that are secure, resilient and capable of spanning air, land, sea and space.

Forward Guidance

Leidos is updating its fiscal year 2023 guidance as follows:

	FY23 Guidance							
Measure	Current	Prior						
Revenues (billions)	\$14.9 - \$15.2	\$14.7 - \$15.1						
Adjusted EBITDA Margin	10.1% - 10.5%	10.3% - 10.5%						
Non-GAAP Diluted EPS	\$6.40 - \$6.80	\$6.40 - \$6.80						
Cash Flows Provided by Operating Activities (millions)	at or above \$700	at or above \$700						

For information regarding adjusted EBITDA margin and non-GAAP diluted EPS, see the related explanations and reconciliations to GAAP measures included elsewhere in this release.

Leidos does not provide a reconciliation of forward-looking adjusted EBITDA margins or non-GAAP diluted EPS to net income due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income may vary significantly based on actual events, Leidos is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected net income and diluted EPS being materially less than what may be implied by projected adjusted EBITDA margins and non-GAAP diluted EPS.

Conference Call Information

Leidos management will discuss operations and financial results in an earnings conference call beginning at 8:00 A.M. eastern time on August 1, 2023. Analysts and institutional investors may participate by dialing +1 (877) 869-3847 (toll-free U.S.) or +1 (201) 689-8261 (international callers).

A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Leidos Investor Relations website (<u>http://ir.leidos.com</u>).

After the call concludes, an audio replay can be accessed on the Leidos Investor Relations website or by dialing +1 (877) 660-6853 (toll-free U.S.) or +1 (201) 612-7415 (international callers) and entering conference ID 13739546.

About Leidos

Leidos is a Fortune 500[®] technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil and health markets. Leidos' 46,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately \$14.4 billion for the fiscal year ended December 30, 2022.

3

For more information, visit www.leidos.com.

Forward-Looking Statements

Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements in this release include, among others, estimates of our future growth, strategy and financial and operating performance, including future revenues, adjusted EBITDA margins, diluted EPS (including on a non-GAAP basis) and cash flows provided by operating activities, as well as statements about our business contingency plans, government budgets and the ongoing Continuing Resolution, uncertainties in tax due to new tax legislation or other regulatory developments, strategy, planned investments, sustainability goals and our future dividends, share repurchases, capital expenditures, debt repayments, acquisitions, dispositions and cash flow conversion. These statements reflect our belief and assumptions as to future events that may not prove to be accurate.

Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this release depending on a variety of factors, including, but not limited to: developments in the U.S. government defense and nondefense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the U.S. government budget process or a government shutdown, or the U.S. government's failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; rising inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company: our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to respond rapidly to emerging technology trends, including the use of artificial intelligence; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of health epidemics, pandemics and similar outbreaks may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer and disposal, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments: our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts; the failure of our inspection or detection systems to detect threats: the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to declare or increase future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements; our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects; our ability to successfully integrate acquired businesses; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face.

These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission ("SEC"), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, all of which may be viewed or obtained through the Investor Relations section of our website at www.leidos.com.

All information in this release is as of August 1, 2023. Leidos expressly disclaims any duty to update the guidance or any other forwardlooking statement provided in this release to reflect subsequent events, actual results or changes in Leidos' expectations. Leidos also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

CONTACTS:

Investor Relations: Stuart Davis 571.526.6124 ir@leidos.com Media Relations: Melissa Lee Dueñas 571.526.6850 Duenasml@leidos.com

LEIDOS HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions, except per share amounts)

	Three Mo	nths E	Six Months Ended				
	June 30, 2023		July 1, 2022	 June 30, 2023		July 1, 2022	
Revenues	\$ 3,838	\$	3,597	\$ 7,537	\$	7,091	
Cost of revenues	3,271		3,059	6,475		6,041	
Selling, general and administrative expenses	237		262	470		498	
Acquisition, integration and restructuring costs	6		5	9		8	
Asset impairment charges	—		3	—		3	
Equity earnings of non-consolidated subsidiaries	(7)		(3)	(13)		(1)	
Operating income	 331		271	 596		542	
Non-operating expense:							
Interest expense, net	(56)		(50)	(110)		(98)	
Other (expense) income, net	 (1)		4	 (5)		3	
Income before income taxes	274		225	481		447	
Income tax expense	(64)		(53)	 (107)		(98)	
Net income	 210		172	 374		349	
Less: net income attributable to non-controlling interest	3		1	5		3	
Net income attributable to Leidos common stockholders	\$ 207	\$	171	\$ 369	\$	346	
Earnings per share:							
Basic	\$ 1.51	\$	1.25	\$ 2.69	\$	2.51	
Diluted	1.50		1.24	2.67		2.49	
Weighted average number of common shares outstanding:							
Basic	137		137	137		138	
Diluted	138		138	138		139	
Diatou	100		100	100		100	
Cash dividends declared per share	\$ 0.36	\$	0.36	\$ 0.72	\$	0.72	

LEIDOS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except par value)

		June 30, 2023	De	cember 30, 2022
	(u	naudited)		
Assets:				
Cash and cash equivalents	\$	329	\$	516
Receivables, net		2,478		2,350
Inventory, net		310		287
Other current assets		459		490
Total current assets		3,576		3,643
Property, plant and equipment, net		928		847
Intangible assets, net		851		952
Goodwill		6,701		6,696
Operating lease right-of-use assets, net		534		545
Other long-term assets		436		388
Total assets	\$	13,026	\$	13,071
Liabilities:				
Accounts payable and accrued liabilities	\$	1,970	\$	2,254
Accrued payroll and employee benefits	Ŧ	666	Ψ	701
Short-term debt and current portion of long-term debt		219		992
Total current liabilities		2,855		3,947
Long-term debt, net of current portion		4,670		3,928
Operating lease liabilities		553		570
Deferred tax liabilities		16		40
Other long-term liabilities		279		233
Total liabilities		8,373		8,718
Stockholders' equity:				
Common stock, \$0.0001 par value, 500 million shares authorized, 137 million and 137 million shares issued and outstanding at June 30, 2023, and December 30, 2022, respectively		_		_
Additional paid-in capital		2,024		2,005
Retained earnings		2,636		2,367
Accumulated other comprehensive loss		(63)		(73)
Total Leidos stockholders' equity		4,597		4,299
Non-controlling interest		56		54
Total stockholders' equity		4,653		4,353
Total liabilities and stockholders' equity	\$	13,026	\$	13,071

LEIDOS HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)

June 30, 2023 June 30, 2023 June 30, 2024 June 30, 2024 June 30, 2024 Cash flows from operations: 5 210 \$ 172 \$ 374 \$ 349 Adjustments to reconcile net income to net cash provided by operations: 84 83 166 168 Depreciation and amortization 19 19 37 35 Deferred income taxes (45) (75) (88) (138) Other 1 3 6 7 Change in assets and liabilities, net of effects of acquisitions and dispositions: 43 (6) (123) (228) Accounts payable and accrued liabilities and other long-term liabilities (101) (206) (218) (266) Accruse taxe receivables (45) (23) (125) 445 Net cash provided by operating activities: 164 45 66 138 Cash flows from investing activities: - 6 - 16 Net cash used in investing activities: - 6 - 16 Net		_	Three Mor	nths I	Ended		nded		
Net income \$ 210 \$ 172 \$ 374 \$ 349 Adjustments to reconcile net income to net cash provided by operations:		J			July 1, 2022				July 1, 2022
Adjustments to reconcile net income to net cash provided by operations: 84 83 166 168 Depreciation and amortization 19 19 37 35 Deferred income taxes (45) (75) (88) (136) Other 1 3 6 7 Change in assets and liabilities, net of effects of acquisitions and dispositions:	Cash flows from operations:								
Depreciation and amoritzation 84 83 166 168 Stock-based compensation 19 19 37 35 Deferred income taxes (45) (75) (88) (136) Other 1 3 6 7 Change in assets and liabilities, net of effects of acquisitions and dispositions: 43 (6) (123) (238) Other current assets and other long-term assets 58 101 49 73 Accounts payable and accrued liabilities and other long-term liabilities (101) (206) (198) (266) Accrued payroll and employee benefits (45) (66) (23) (125) 45 Net cash provided by operating activities: 164 45 66 138 Cash flows from investing activities: - 6 - 15 Payments for property, equipment and software (40) (21) (79) (48) Net proceeds from sale of assets - 6 - 15 Payments form debt issuance - 800 1	Net income	\$	210	\$	172	\$	374	\$	349
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Adjustments to reconcile net income to net cash provided by operations:								
Deferred income taxes (45) (75) (88) (136) Other 1 3 6 7 Change in assets and liabilities, net of effects of acquisitions and dispositions:	Depreciation and amortization		84		83		166		168
Other 1 3 6 7 Change in assets and liabilities, net of effects of acquisitions and dispositions: Receivables 43 (6) (123) (238) Receivables 43 (6) (123) (238) (248) Other current assets and other long-term assets 58 101 49 73 Accounts payable and accrued liabilities and other long-term liabilities (101) (206) (198) (266) Accrued payroll and employee benefits (45) (23) (125) 45 Net cash provided by operating activities: (44) 45 66 138 Cash flows from investing activities: — 6 — 15 Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets — 6 — 1 _ 1 _ 1 _ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Stock-based compensation		19		19		37		35
Change in assets and liabilities, net of effects of acquisitions and dispositions: Receivables43(6)(123)(238)Other current assets and other long-term assets581014973Accounts payable and accrued liabilities and other long-term liabilities(101)(206)(198)(266)Accrued payroll and employee benefits(45)(23)(32)(112)45Net cash provided by operating activities1644566138Cash flows from investing activities:-6-15Acquisition of a business, net of cash acquired(4)-(4)(2)Divestiture of a business-6-16Payments for property, equipment and software(40)(21)(79)(49)Net proceeds from sale of assets-6-6Other-1-1-1Net cash used in investing activities(44)(8)(83)(29)Cash flows from financing activities:-3801,743380Proceeds from commercial paper20075200150Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs7-Dividend payments(50)(49)(100)(100)(100)Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs(2)(1) <td>Deferred income taxes</td> <td></td> <td>(45)</td> <td></td> <td>(75)</td> <td></td> <td>(88)</td> <td></td> <td>(136)</td>	Deferred income taxes		(45)		(75)		(88)		(136)
dispositions: Receivables43(6)(123)(238) (238)Other current assets and other long-term assets581014973Accounts payable and accrued liabilities and other long-term liabilities(101)(206)(198)(266)Accrued payroll and employee benefits(45)(23)(32)1011000(23)(125)45Net cash provided by operating activities164456613838231014973Acquisition of a business, net of cash acquired(4)-(4)(2)(21)(79)(49)Divestiture of a business, net of cash acquired-6-15-6-1-11Net proceeds from sale of assets-6-6-618(23)(29)(29)(44)(8)(83)(29)Cash flows from financing activities(44)(8)(83)(29)(29)150150160149100)100)Proceeds from commercial paper2007520015015013102522101(3)(3)(3)(3)(21)(513)<	Other		1		3		6		7
Other current assets and other long-term assets 58 101 49 73 Accounts payable and accrued liabilities and other long-term liabilities (101) (206) (198) (266) Accrued payroll and employee benefits (45) (23) (125) 45 Net cash provided by operating activities: 164 45 66 138 Cash flows from investing activities: - 6 - 15 Aquisition of a business, net of cash acquired (4) - (4) (2) Divestiture of a business, net of cash acquired - 6 - 15 Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets - 6 - 1 - 1 Proceeds from financing activities: - 164 (8) (83) (29) Cash flows from financing activities: - 6 - 16 - 16 - 16 0 163 133 100 25 220 150									
Accounts payable and accrued liabilities and other long-term liabilities (101) (206) (198) (266) Accrued payroll and employee benefits (45) (23) (32) 101 Income taxes receivable/payable (60) (23) (125) 45 Net cash provided by operating activities 164 45 66 138 Cash flows from investing activities: - 6 - (2) Divestiture of a business - 6 - 15 Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets - 6 - 6 Other - 1 - 1 - Net cash used in investing activities: - 380 1,743 380 Net proceeds from commercial paper 200 75 200 150 Repayments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) <	Receivables		43		(6)		(123)		(238)
Accrued payroll and employee benefits (45) (23) (32) 101 Income taxes receivable/payable (60) (23) (125) 45 Net cash provided by operating activities 164 45 66 138 Cash flows from investing activities: - 6 - 15 Acquisition of a business, net of cash acquired (4) - (4) (2) Divestiture of a business - 6 - 15 Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets - 6 - 1 - 1 1 1 Net cash used in investing activities: (44) (8) (83) (29) (20) 75 200 150 Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance - - 7 - Dividend payments of stock and other - (2) (43) (528) Proceeds from issuances of stock 13 10 25 22 143 (528) 22 13	Other current assets and other long-term assets		58		101		49		73
Income taxes receivable/payable (60) (23) (125) 45 Net cash provided by operating activities 164 45 66 138 Cash flows from investing activities - 6 - 15 Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets - 6 - 6 Other - 1 - 1 Net cash used in investing activities: (44) (8) (83) (29) Cash flows from financing activities: - 380 1,743 380 Proceeds from debt issuance - 380 1,743 380 Net proceeds from commercial paper 200 75 200 150 Repayments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repayments for debt issuance costs - - (7) - Dividend payments (50) (49)	Accounts payable and accrued liabilities and other long-term liabilities		(101)		(206)		(198)		(266)
Net cash provided by operating activities1644566138Cash flows from investing activities:(4)-(4)(2)Divestiture of a business, net of cash acquired(4)-(4)(2)Divestiture of a business-6-15Payments for property, equipment and software(40)(21)(79)(49)Net proceeds from sale of assets-6-6Other-1-1-Net cash used in investing activities(44)(8)(83)(29)Cash flows from financing activities:-3801,743380Proceeds from debt issuance-3801,743380Net proceeds from commercial paper20075200150Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs(7)-Dividend payments(50)(49)(100)(100)Repurchases of stock and other-(2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net capital distributions to non-controlling interests(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash(43)38(225)(409)Cash, cash equivalents and restricted cash at beginning of period491<	Accrued payroll and employee benefits		(45)		(23)		(32)		101
Cash flows from investing activities:Acquisition of a business, net of cash acquired(4)-(4)(2)Divestiture of a business-6-15Payments for property, equipment and software(40)(21)(79)(49)Net proceeds from sale of assets-6-6Other-1-11Net cash used in investing activities:(44)(8)(83)(29)Cash flows from financing activities:-3801,743380Proceeds from debt issuance-3801,743380Net proceeds from commercial paper20075200150Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs(7)-Dividend payments(50)(49)(100)(100)(100)Repurchases of stock and other-(2)(13)(5)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net capital distributions to non-controlling interests(2)(1)(3)(5)Net	Income taxes receivable/payable		(60)		(23)		(125)		45
Acquisition of a business, net of cash acquired (4) - (4) (2) Divestiture of a business-6-15Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets-6-6Other-1-1Net cash used in investing activities (44) (8) (83) (29) Cash flows from financing activities:-380 $1,743$ 380Net proceeds from debt issuance-380 $1,743$ 380Net proceeds from commercial paper20075200150Repayments of borrowings (325) (407) $(2,036)$ (434) Payments for debt issuance costs (7) -Dividend payments (50) (49) (100) (100) Repurchases of stock and other- (2) (1) (3) Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests (2) (1) (3) (3) Proceeds increase in cash, cash equivalents and restricted cash1 (5) 3 (5) Net (decrease) increase in cash, cash equivalents and restricted cash at end of period 448 466 448 466 Less: restricted cash at end of period 419 127 119 127	Net cash provided by operating activities		164		45		66		138
Divestiture of a business $ 6$ $ 15$ Payments for property, equipment and software(40)(21)(79)(49)Net proceeds from sale of assets $ 6$ $ 6$ Other $ 1$ $ 1$ Net cash used in investing activities(44)(8)(83)(29)Cash flows from financing activities: $ 380$ $1,743$ 380 Proceeds from debt issuance $ 380$ $1,743$ 380 Net proceeds from commercial paper 200 75 200 150 Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs $ (7)$ $-$ Dividend payments(50)(49)(100)(100)Repurchases of stock and other $ (2)$ (43) (528) Proceeds from issuances of stock1310 25 222 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net capital distributions to non-controlling interests (2) (1) (3) (3) Seffect of foreign exchange rate changes on cash, cash equivalents and restricted cash (43) 38 (235) (409) Net (decrease) increase in cash, cash equivalents and restricted cash (43) 38 (235) (409) Cash, cash equivalents and restricted cash at beginning of period 491 428 683 875 Cash, cash equivalents and re	Cash flows from investing activities:								
Payments for property, equipment and software (40) (21) (79) (49) Net proceeds from sale of assets - 6 - 6 Other - 1 - 1 Net cash used in investing activities (44) (8) (83) (29) Cash flows from financing activities: - 380 1,743 380 Proceeds from commercial paper 200 75 200 150 Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repurchases of stock and other - (2) (43) (528) Proceeds from issuances of stock 13 10 25 221 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net cash (used in) provided by financing activities (164) 6 (221) (513) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash 1 (5) 3	Acquisition of a business, net of cash acquired		(4)		—		(4)		(2)
Net proceeds from sale of assets - 6 - 6 Other - 1 - 1 Net cash used in investing activities (44) (8) (83) (29) Cash flows from financing activities: - 380 1,743 380 Proceeds from debt issuance - 380 1,743 380 Net proceeds from commercial paper 200 75 200 150 Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repurchases of stock and other - (2) (43) (528) Proceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests (2) (1) (3) (3) Perceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests	Divestiture of a business		_		6		_		15
Other $-$ 1 $-$ 1Net cash used in investing activities(44)(8)(83)(29)Cash flows from financing activities: $-$ 3801,743380Proceeds from debt issuance $-$ 3801,743380Net proceeds from commercial paper20075200150Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs $ -$ (7) $-$ Dividend payments(50)(49)(100)(100)Repurchases of stock and other $-$ (2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash(43)38(235)(409)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Payments for property, equipment and software		(40)		(21)		(79)		(49)
Net cash used in investing activities(44)(8)(83)(29)Cash flows from financing activities: $-$ 3801,743380Proceeds from debt issuance $-$ 3801,743380Net proceeds from commercial paper20075200150Repayments of borrowings(325)(407)(2,036)(434)Payments for debt issuance costs $ -$ (7) $-$ Dividend payments(50)(49)(100)(100)Repurchases of stock and other $-$ (2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash(43)38(235)(409)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at end of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Net proceeds from sale of assets		_		6		_		6
Cash flows from financing activities: $ 380$ $1,743$ 380 Proceeds from debt issuance $ 380$ $1,743$ 380 Net proceeds from commercial paper 200 75 200 150 Repayments of borrowings (325) (407) $(2,036)$ (434) Payments for debt issuance costs $ (7)$ $-$ Dividend payments (50) (49) (100) (100) Repurchases of stock and other $ (2)$ (43) (528) Proceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net cash (used in) provided by financing activities (164) 6 (221) (513) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (43) 38 (235) (409) Net (decrease) increase in cash, cash equivalents and restricted cash (43) 38 (235) (409) Cash, cash equivalents and restricted cash at beginning of period 491 428 683 875 Cash, cash equivalents and restricted cash at end of period 448 466 448 466 Less: restricted cash at end of period 119 127 119 127	Other		—				—		1
Proceeds from debt issuance - 380 1,743 380 Net proceeds from commercial paper 200 75 200 150 Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repurchases of stock and other - - (2) (43) (528) Proceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net cash (used in) provided by financing activities (164) 6 (221) (513) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (43) 38 (235) (409) Cash, cash equivalents and restricted cash at beginning of period 491 428 683 875 Cash, cash equivalents and restricted cash at end of period 448 466 448 466 Less: restricted cash at end	Net cash used in investing activities		(44)		(8)		(83)		(29)
Net proceeds from commercial paper 200 75 200 150 Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repurchases of stock and other - (2) (43) (528) Proceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net cash (used in) provided by financing activities (164) 6 (221) (513) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (43) 38 (235) (409) Cash, cash equivalents and restricted cash at beginning of period 491 428 683 875 Cash, cash equivalents and restricted cash at end of period 448 466 448 466 Less: restricted cash at end of period 119 127 119 127	Cash flows from financing activities:								
Repayments of borrowings (325) (407) (2,036) (434) Payments for debt issuance costs - - (7) - Dividend payments (50) (49) (100) (100) Repurchases of stock and other - (2) (43) (528) Proceeds from issuances of stock 13 10 25 22 Net capital distributions to non-controlling interests (2) (1) (3) (3) Net cash (used in) provided by financing activities (164) 6 (221) (513) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (43) 38 (235) (409) Cash, cash equivalents and restricted cash at beginning of period 491 428 683 875 Cash, cash equivalents and restricted cash at end of period 448 466 448 466 Less: restricted cash at end of period 119 127 119 127	Proceeds from debt issuance		—		380		1,743		380
Payments for debt issuance costs(7)-Dividend payments(50)(49)(100)(100)Repurchases of stock and other-(2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period119127119127	Net proceeds from commercial paper		200		75		200		150
Dividend payments(50)(49)(100)(100)Repurchases of stock and other-(2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Repayments of borrowings		(325)		(407)		(2,036)		(434)
Repurchases of stock and other-(2)(43)(528)Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Payments for debt issuance costs		—		—		(7)		—
Proceeds from issuances of stock13102522Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Dividend payments		(50)		(49)		(100)		(100)
Net capital distributions to non-controlling interests(2)(1)(3)(3)Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Repurchases of stock and other		_		(2)		(43)		(528)
Net cash (used in) provided by financing activities(164)6(221)(513)Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Proceeds from issuances of stock		-		10				22
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127			(2)		(1)		(3)		
restricted cash1(5)3(5)Net (decrease) increase in cash, cash equivalents and restricted cash(43)38(235)(409)Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127			(164)		6		(221)		(513)
Cash, cash equivalents and restricted cash at beginning of period491428683875Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127			1		(5)		3		(5)
Cash, cash equivalents and restricted cash at end of period448466448466Less: restricted cash at end of period119127119127	Net (decrease) increase in cash, cash equivalents and restricted cash		(43)		38		(235)		(409)
Less: restricted cash at end of period 119 127 119 127	Cash, cash equivalents and restricted cash at beginning of period		491		428		683		875
	Cash, cash equivalents and restricted cash at end of period		448		466		448		466
Cash and cash equivalents at end of period \$ 329 \$ 339 \$ 329 \$ 339	Less: restricted cash at end of period		119		127		119		127
	Cash and cash equivalents at end of period	\$	329	\$	339	\$	329	\$	339

LEIDOS HOLDINGS, INC. UNAUDITED SEGMENT OPERATING RESULTS (in millions)

	Three Mor	nths E	Ended	Six Months Ended				
	 June 30, 2023	July 1, 2022			June 30, 2023		July 1, 2022	
Revenues:								
Defense Solutions	\$ 2,187	\$	2,052	\$	4,299	\$	4,101	
Civil	902		857		1,779		1,652	
Health	 749		688		1,459		1,338	
Total	\$ 3,838	\$	3,597	\$	7,537	\$	7,091	
Operating income (loss):								
Defense Solutions	\$ 175	\$	139	\$	322	\$	272	
Civil	64		38		104		81	
Health	122		126		229		244	
Corporate	(30)		(32)		(59)		(55)	
Total	\$ 331	\$	271	\$	596	\$	542	
Operating income margin:								
Defense Solutions	8.0 %		6.8 %		7.5 %		6.6 %	
Civil	7.1 %		4.4 %		5.8 %		4.9 %	
Health	16.3 %		18.3 %		15.7 %		18.2 %	
Total	8.6 %		7.5 %		7.9 %		7.6 %	

Defense Solutions

Defense Solutions revenues of \$2.19 billion increased by 7% compared to the prior year quarter. Revenue growth was primarily in the areas of digital modernization, including the Navy Next Generation Enterprise Network Recompete (NGEN-R) Service Management, Integration and Transport (SMIT) contract, and hypersonics, including the Space Defense Agency (SDA) Wide Field of View (WFOV) programs. For the quarter Defense Solutions operating income margin increased to 8.0% from 6.8% in the prior year quarter, and non-GAAP operating income margin increase in segment profitability was attributable to improved business mix and program execution as well as lower indirect spending.

<u>Civil</u>

Civil revenues of \$902 million increased by 5% compared to the prior year quarter. The primary drivers of revenue growth were the National Aeronautics and Space Administration (NASA) Advanced Enterprise Global Information Technology Solutions (AEGIS) program, increased demand for engineering support to commercial energy companies, and a partial recovery within the security products portfolio. Civil operating income margin for the quarter was 7.1%, compared to 4.4% in the prior year quarter, and non-GAAP operating income margin was 9.1%, compared to 6.5% in the prior year quarter. In addition to improvements from business mix, program execution, and cost control, year-over-year segment profitability increased as a result of an adverse arbitration ruling and associated legal fees totaling \$17 million in the second quarter of 2022.

<u>Health</u>

Health revenues of \$749 million increased by 9% compared to the prior year quarter driven by growth on the Social Security Administration (SSA) Information Technology Support Services Contract II (ITSSC II) and higher levels of medical examinations, based on increased volumes, greater market share, and new wins. Health operating income margin for the quarter was 16.3%, compared to 18.3% in the prior year quarter, and non-GAAP operating margin was 17.0%, compared to 19.8% in the prior year quarter. The decrease in segment profitability was driven primarily by the \$28 million equitable adjustment in the second quarter of 2022 to cover costs incurred as a result of the COVID-19 pandemic.

LEIDOS HOLDINGS, INC. UNAUDITED BACKLOG BY REPORTABLE SEGMENT (in millions)

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts. Backlog value is based on management's estimates about volume of services, availability of customer funding and other factors, and excludes contracts that are under protest. Estimated backlog comprises both funded and negotiated unfunded backlog. Backlog estimates are subject to change and may be affected by several factors, including modifications of contracts, non-exercise of options and foreign currency movements.

Funded backlog for contracts with the U.S. government represents the value on contracts for which funding is appropriated less revenues previously recognized on these contracts. Funded backlog for contracts with non-U.S. government entities and commercial customers represents the estimated value on contracts, which may cover multiple future years, under which Leidos is obligated to perform, less revenue previously recognized on the contracts.

Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from contracts for which funding has not been appropriated and unexercised priced contract options. Negotiated unfunded backlog does not include unexercised option periods and future potential task orders expected to be awarded under IDIQ, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded or separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.

The estimated value of backlog as of the dates presented was as follows:

	June 30, 2023						July 1, 2022						
Segment	 Funded		Unfunded		Total		Funded		Unfunded		Total		
Defense Solutions	\$ 4,904	\$	13,500	\$	18,404	\$	4,351	\$	13,668	\$	18,019		
Civil	2,134		7,710		9,844		2,051		8,846		10,897		
Health	1,233		4,671		5,904		1,139		4,667		5,806		
Total	\$ 8,271	\$	25,881	\$	34,152	\$	7,541	\$	27,181	\$	34,722		

Total backlog as of June 30, 2023, as compared to July 1, 2022, included \$610 million of backlog acquired through a business combination in the Defense Solutions reportable segment.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES

Leidos uses and refers to organic revenue, non-GAAP operating income, non-GAAP operating margin, adjusted EBITDA, adjusted EBITDA margin, non-GAAP diluted EPS, non-GAAP free cash flow and non-GAAP free cash flow conversion, which are not measures of financial performance under generally accepted accounting principles in the U.S. and, accordingly, these measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be read in conjunction with Leidos's consolidated financial statements prepared in accordance with GAAP.

Management believes that these non-GAAP measures provide another representation of the results of operations and financial condition, including its ability to comply with financial covenants. These non-GAAP measures are frequently used by financial analysts covering Leidos and its peers. The computation of non-GAAP measures may not be comparable to similarly titled measures reported by other companies, thus limiting their use for comparability.

Organic revenues capture the revenue that is inherent in the underlying business excluding the impact of acquisitions and divestitures made within the prior year; it is computed as current revenues excluding revenues from acquisitions within the last 12 months and divestitures within the current and year-ago periods.

Non-GAAP operating income is computed by excluding the following discrete items from operating income:

- Acquisition, integration and restructuring costs Represents acquisition, integration, lease termination, severance and retention costs related to acquisitions.
- Amortization of acquired intangible assets Represents the amortization of the fair value of the acquired intangible assets.
- Asset impairment charges Represents impairments of long-lived intangible assets.

Non-GAAP operating margin is computed by dividing non-GAAP operating income by revenues.

Adjusted EBITDA is computed by excluding the following items from income before income taxes: (i) discrete items as identified above; (ii) interest expense; (iii) interest income; (iv) depreciation expense; and (v) amortization of internally developed intangible assets.

Adjusted EBITDA margin is computed by dividing adjusted EBITDA by revenues.

Non-GAAP net income is computed by excluding the discrete items listed under non-GAAP operating income and their related tax impacts.

Non-GAAP diluted EPS is computed by dividing net income attributable to Leidos common stockholders, adjusted for the discrete items as identified above and the related tax impacts, by the diluted weighted average number of common shares outstanding.

Non-GAAP free cash flow is computed by deducting expenditures for property, equipment and software from net cash provided by operating activities.

Non-GAAP free cash flow conversion is computed by dividing non-GAAP free cash flow by non-GAAP net income attributable to Leidos common stockholders; operating cash flow conversion is computed by dividing net cash provided by operating activities by net income attributable to Leidos shareholders.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except growth percentages)

The following table presents the reconciliation of revenues to organic revenues by reportable segment and total operations:

	Three Mo	nths	Ended	
	 June 30, 2023	July 1, 2022		Percent Change
Defense Solutions				
Revenues, as reported	\$ 2,187	\$	2,052	7 %
Acquisition revenues ⁽¹⁾	28		_	
Organic revenues	\$ 2,159	\$	2,052	5 %
Civil				
Revenues, as reported	\$ 902	\$	857	5 %
Health				
Revenues, as reported	\$ 749	\$	688	9 %
Total Operations				
Revenues, as reported	\$ 3,838	\$	3,597	7 %
Acquisition revenues ⁽¹⁾	28		_	
Organic revenues	\$ 3,810	\$	3,597	6 %

(1) Current period acquisition revenues reflect revenues in the current as reported figures for 12 months from closing of each acquisition. For the three months ended June 30, 2023, Defense Solutions segment acquisition revenues include the acquisition of Cobham Special Missions that was completed on October 30, 2022.

UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except per share amounts and margin percentages)

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the three months ended June 30, 2023:

	Three Months Ended June 30, 2023										
	As reported	Acquisition, integration and restructuring costs	Amortization of acquired intangibles	Non-GAAP results							
Operating income	\$ 331	\$ 6	\$ 51	\$ 388							
Non-operating expense, net	(57)	—	—	(57)							
Income before income taxes	274	6	51	331							
Income tax expense ⁽¹⁾	(64)	(2)	(13)	(79)							
Net income	 210	4	38	252							
Less: net income attributable to non-controlling interest	3	—	—	3							
Net income attributable to Leidos common stockholders	\$ 207	\$ 4	\$ 38	\$ 249							
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$ 1.50	\$ 0.03	\$ 0.28	\$ 1.80							
Diluted shares	138	138	138	138							

	Three Months Ended June 30, 2023										
		As reported	Acquisition, integration and restructuring costs	Amortization of acquired intangibles	Non-0	GAAP results					
Net income	\$	210	\$ 4	\$ 38	\$	252					
Income tax expense ⁽¹⁾		64	2	13		79					
Income before income taxes		274	6	51		331					
Depreciation expense		33	—	_		33					
Amortization of intangibles		51	_	(51)							
Interest expense, net		56	—	_		56					
EBITDA	\$	414	\$ 6	\$ —	\$	420					
EBITDA margin		10.8 %				10.9 %					

(1) Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

(2) Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except per share amounts and margin percentages)

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the three months ended July 1, 2022:

		Thre	e M	Ionths Ended July 1,	202	2		
	As reported	Acquisition, integration and restructuring costs	a	Amortization of acquired intangibles	A	sset impairment charges	No	on-GAAP results
Operating income	\$ 271	\$5	\$	5 7	\$	3	\$	336
Non-operating expense, net	 (46)							(46)
Income before income taxes	225	5		57		3		290
Income tax expense ⁽¹⁾	(53)	(1))	(15)		(1)		(70)
Net income	 172	4		42		2		220
Less: net income attributable to non-controlling interest	1	_		—		—		1
Net income attributable to Leidos common stockholders	\$ 171	\$ 4	\$	\$ 42	\$	2	\$	219
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$ 1.24	\$ 0.03	\$	\$ 0.31	\$	0.01	\$	1.59
Diluted shares	138	138		138		138		138

			Three	Months Ended July 1	202	2		
	As reported	i re	Acquisition, integration and structuring costs	Amortization of acquired intangibles	A	sset impairment charges	No	n-GAAP results
Net income	\$ 172	\$	4	\$ 42	\$	2	\$	220
Income tax expense ⁽¹⁾	53		1	15		1		70
Income before income taxes	 225		5	57	_	3		290
Depreciation expense	26			_		_		26
Amortization of intangibles	57		_	(57)		—		_
Interest expense, net	50		—	—		—		50
EBITDA	\$ 358	\$	5	\$ —	\$	3	\$	366
EBITDA margin	 10.0 %							10.2 %

(1) Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

(2) Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except per share amounts and margin percentages)

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the six months ended June 30, 2023:

		Six Months End	ed June 30, 2023	
	 As reported	Acquisition, integration and restructuring costs	Amortization of acquired intangibles	Non-GAAP results
Operating income	\$ 596	\$ 9	\$ 103	\$ 708
Non-operating expense, net	(115)	—	—	(115)
Income before income taxes	481	9	103	593
Income tax expense ⁽¹⁾	(107)	(2)	(27)	(136)
Net income	374	7	76	457
Less: net income attributable to non-controlling interest	5	—	—	5
Net income attributable to Leidos common stockholders	\$ 369	\$ 7	\$ 76	\$ 452
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$ 2.67	\$ 0.05	\$ 0.55	\$ 3.28
Diluted shares	138	138	138	138

		:	Six Months End	ed June 30, 2023		
	As reported	in	Acquisition, itegration and tructuring costs	Amortization of acquired intangibles	Nor	-GAAP results
Net income	\$ 374	\$	7	\$ 76	\$	457
Income tax expense ⁽¹⁾	107		2	27		136
Income before income taxes	481		9	103		593
Depreciation expense	63		_	—		63
Amortization of intangibles	103		—	(103)		—
Interest expense, net	110		—	—		110
EBITDA	\$ 757	\$	9	\$ —	\$	766
EBITDA margin	 10.0 %					10.2 %

(1) Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

(2) Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except per share amounts and margin percentages)

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the six months ended July 1, 2022:

			Six M	Мо	nths Ended July 1, 2	022	2		
		As reported	Acquisition, integration and estructuring costs	a	Amortization of cquired intangibles	А	sset impairment charges	N	on-GAAP results
Operating income	\$	542	\$ 8	\$	115	\$	3	\$	668
Non-operating expense, net		(95)	 		—		_		(95)
Income before income taxes		447	8	_	115		3		573
Income tax expense ⁽¹⁾		(98)	(2)		(29)		(1)		(130)
Net income	_	349	6		86		2		443
Less: net income attributable to non-controlling interest		3	—		—		—		3
Net income attributable to Leidos common stockholders	\$	346	\$ 6	\$	86	\$	2	\$	440
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$	2.49	\$ 0.04	\$	0.63	\$	0.01	\$	3.17
Diluted shares		139	139		139		139		139

				Six	Months Ended July 1, 2	2022			
		As reported	inte	Acquisition, egration and ructuring costs	Amortization of acquired intangibles	As	set impairment charges	Non	-GAAP results
Net income	\$	349	\$	6	\$ 86	\$	2	\$	443
Income tax expense ⁽¹⁾		98		2	29		1		130
Income before income taxes	-	447		8	115		3		573
Depreciation expense		52			_		—		52
Amortization of intangibles		116		—	(115)		—		1
Interest expense, net		98		—	_		—		98
EBITDA	\$	713	\$	8	\$ —	\$	3	\$	724
EBITDA margin		10.1 %							10.2 %

(1) Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

(2) Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except margin percentages)

The following tables present the reconciliation of non-GAAP operating income by reportable segment and Corporate to operating income:

	_		Three I	Month	s Ended June	e 30, 20	23	
	Oper	ating e (loss)	Acquisition, integration and restructuring costs		nortization of acquired ntangibles	op	n-GAAP erating me (loss)	Non-GAAP operating margin
Defense Solutions	\$	175	\$ —	\$	29	\$	204	9.3 %
Civil		64	1		17		82	9.1 %
Health		122	_		5		127	17.0 %
Corporate		(30)	5		_		(25)	NM
Total	\$	331	\$6	\$	51	\$	388	10.1 %

					Т	hree Months Er	ndeo	d July 1, 2022			
	Operati income (l		integ	equisition, gration and structuring costs		nortization of acquired intangibles		Asset Impairment Charges	(lon-GAAP operating come (loss)	Non-GAAP operating margin
Defense Solutions	\$	139	\$		\$	32	\$	_	\$	171	8.3 %
Civil		38		—		18		—		56	6.5 %
Health		126		—		7		3		136	19.8 %
Corporate		(32)		5		—		—		(27)	NM
Total	\$	271	\$	5	\$	57	\$	3	\$	336	9.3 %

			Six Mo	onthe	Ended June	30, 202	23	
	Operating income (los		Acquisition, integration and restructuring costs		nortization of acquired intangibles	o	on-GAAP perating ome (loss)	Non-GAAP operating margin
Defense Solutions	\$ 3	22	\$ —	\$	59	\$	381	8.9 %
Civil	1	04	1		33		138	7.8 %
Health	2	29	_		11		240	16.4 %
Corporate	(59)	8		—		(51)	NM
Total	\$5	96	\$9	\$	103	\$	708	9.4 %

				Six Months End	ded	July 1, 2022		
	Operating income (loss	5)	Acquisition, integration and restructuring costs	nortization of acquired intangibles		Asset Impairment Charges	Non-GAAP operating ncome (loss)	Non-GAAP operating margin
Defense Solutions	\$ 27	2	\$ —	\$ 65	\$	_	\$ 337	8.2 %
Civil	8	1	—	36		—	117	7.1 %
Health	24	.4	_	14		3	261	19.5 %
Corporate	(5	5)	8	—		—	(47)	NM
Total	\$ 54	2	\$ 8	\$ 115	\$	3	\$ 668	9.4 %

NM - Not Meaningful

LEIDOS HOLDINGS, INC.

UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except percentages)

The following table presents the reconciliation of non-GAAP free cash flow to net cash provided by operating activities as well as the calculation of operating cash flow and non-GAAP free cash flow conversion ratios:

		Three Mo	nths End	ed
	June	30, 2023	Ju	ly 1, 2022
Net cash provided by operating activities ⁽¹⁾	\$	164	\$	45
Payments for property, equipment and software		(40)		(21)
Non-GAAP free cash flow	\$	124	\$	24
Net income attributable to Leidos common stockholders	\$	207	\$	171
Acquisition, integration and restructuring costs ⁽²⁾		4		4
Amortization of acquired intangibles ⁽²⁾		38		42
Asset impairment charges ⁽²⁾		_		2
Non-GAAP net income attributable to Leidos common stockholders	\$	249	\$	219
Operating cash flow conversion ratio		79 %		26 %
Non-GAAP free cash flow conversion ratio		50 %		11 %

(1) Prior year financial information has been reclassified to reflect the effect of foreign exchange rate changes on cash, cash equivalents and restricted cash in net cash provided by operating activities.

(2) After-tax expenses excluded from non-GAAP net income.